Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica

Seminars in Arthritis and Rheumatism

Volumn 33, Issue 1, 2003, Pages 38-48

  González Gay, Miguel A ^a   Amoli, Mahsa M ^b   Garcia Porrua, Carlos ^a   Ollier, William E R ^b  

^a HOSPITAL XERAL CALDE   (Spain)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Allelic polymorphisms; Giant cell arteritis; Human leukocyte antigen DRB1; Polymyalgia rheumatica; Tumor necrosis factor

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; CLUSTER ANALYSIS; CORTICOSTEROID THERAPY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GIANT CELL ARTERITIS; HUMAN; IMMUNOGENETICS; INFECTION RISK; MULTIFACTORIAL INHERITANCE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RHEUMATIC POLYMYALGIA; T LYMPHOCYTE ACTIVATION;

EID: 0041826780     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2002.50025     Document Type: Article

References (96)

1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
2. Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Rheum Dis Clin North Am 2001;27:729-49.
3. Healey LA, Wilske KR. Manifestations of giant cell arteritis. Med Clin North Am 1977;61:261-70.
4. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1999;41:1497-504.
5. Gonzalez-Gay MA, Garcia-Porma C, Llorca J, Hajeer AH, Branas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000;79:283-92.
6. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica. A 10 year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80.
7. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 1995;38:369-73.
8. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999;26:1326-32.
9. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Hunder GG. Diagnostic approach in a patient presenting with polymyalgia. Clin Exp Rheumatol 1999;17:276-8.
10. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000;27:2179-84.
11. Gonzalezr-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore) 1999;78:292-308.
12. Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, Rodriguez-Ledo P, Llorca J. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis 2001;60:367-71.
13. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M. Polymalgia rheumatic a in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998;25:1750-5.
14. Wernick R, Davey M, Bonafede P. Familial giant cells arteritis: report of an HLA-typed sibling pair and a review of the literature. Clin Exp Rheumatol 1994;12:63-6.
15. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992,90:2355-61.
16. Weyand CM, Hunder NNH, Hicock KC, Hunder GG, Goronzy JJ. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Arthritis Rheum 1994,37:514-20.
17. Jacobsen S, Baslund B, Madsen HO, Tvede N, Svejgaard A, Garred P. Mannose-binding, lectin variant alleles and HLA-DRB1*04 alleles are independently associated with giant cell arteritis (abstr 1731). Arthritis Rheum 2001;44(suppl):S341.
18. Bignon JD, Barrier J, Soulillou JP, Martin P, Grolleau JY. HLA-DR4 in giant cell arteritis. Tissue Antigens 1984;24:60-2.
19. Combe B, Sany J, Le Quellec A, Clot J, Eliaou JF. Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population. J Rheumatol 1998;25:94-8.
20. Rauzy O, Fort M, Nourhashemi F, Alric L, Juchet H, Ecoiffier M, et al. Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis. Ann Rheum Dis. 2000;59:574-5.
21. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998;25:2140-5.
22. Salvarani C, Boiardi L, Mantovani V, Ranzi A, Cantini F, Olivieri I, et al. HLA-DRB1, DQA1, and DQB1 alleles associated with giant cell arteritis in northern Italy. J Rheumatol 1999;26:2395-9.
23. Richardson JE, Gladman DD, Fam A, Keystone EC. HLA-DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. Arthritis Rheum 1987;30:1293-7.
24. Cid MC, Ercilla G, Vilaseca J, Sanmarti R, Villalta J, Ingelmo M, et al. Polymyalgia rheumatica: a syndrome associated with HLA-DR4 antigen. Arthritis Rheum 1988;31:678-82.
25. Guerne PA, Salvi M, Seitz M, Bruhlmann P, Rivier G, Frey D, et al. Molecular analysis of HLA-DR polymorphism in polymyalgia rheumatica. Swiss Group for Research on HLA in Polymyalgia Rheumatica J Rheumatol 1997;24:671-6.
26. Labbe P, Flipo RM, Fajardy I, Hachulla E, Houvenagel E, Hatron PY, et al. HLA DRB1 polymorphism in rhizomelic pseudo-polyarthritis and Horton disease. Rev Med Interne 1995;16:778-81.
27. Banks PM, Cohen MD, Ginsburg WW, Hunder GG. Immunohistologic and cytochemical studies of temporal arteritis. Arthritis Rheum 1983;26:1201-7.
28. Salvarani C, Cantini F, Olivieri I, Barozzi L, Macchioni L, Niccoli L, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997;127:27-31.
29. Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, Filella X, Esteban MJ, Lopez-Soto A, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002;47:29-35.
30. Mattey DL, Hajeer AH, Dababneh A, Thomson W, Gonzalez-Gay MA, Garcia-Porrua C, et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 2000;43:1749-55.
31. Yang H, Vora DK, Targan SR, Toyoda H, Beaudet AL, Rotter JI. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology 1995;109:440-8.
32. Mycko MP, Kwinkowski M, Tronczynska E, Szymanska B, Selmaj KW. Multiple sclerosis: the increased frequency of the ICAM-1 exon 6 gene point mutation genetic type K469. Ann Neurol 1998;44:70-5.
33. Verity DH, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, Fayyad F, et al. Intercellular adhesion molecule-1 gene polymorphisms in Behçet's disease. Eur J Immunogenet 2000;27:73-6.
34. McLaren AJ, Marshall SE, Haldar NA, Mullighan CG, Fuggle SV, Morris PJ, et al. Adhesion molecule polymorphisms in chronic renal allograft failure. Kidney Int 1999;55:1977-82.
35. Macchioni P, Boiardi L, Meliconi R, Salvarani C, Uguccioni MG, Rossi F, et al. Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of steroid treatment. J Rheumatol 1994;21:1860-4.
36. Meliconi R, Pulsatelli L, Melchiorri C, Frizziero L, Salvarani C, Macchioni P, et al. Synovial expression of cell adhesion molecules in polymyalgia rheumatica. Clin Exp Immunol 1997;107:494-500.
37. Cid MC, Cebrian M, Font C, Coll-Vinent B, Hernandez-Rodriguez J, Esparza J, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 2000;43:184-94.
38. Coll-Vinent B, Vilardell C, Font C, Oristrell J, Hernandez-Rodriguez J, Yagüe J, et al. Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis 1999;58:189-92.
39. Vora DK, Rosenbloom CL, Beaudet AL, Cottingham RW. Polymorphisms and linkage analysis for ICAM-1 and the selectin gene cluster. Genomics 1994;21:473-7.
40. Salvarani C, Casali B, Boiardi L, Ranzi A, Macchioni P, Nicoli D, et al. Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 2000;27:1215-21.
41. Amoli MM, Shelley E, Mattey DL, Garcia-Porrua C, Thomson W, Hajeer AH, et al. Lack of association between intercellular adhesion molecule-1 gene polymorphisms and giant cell arteritis. J Rheumatol 2001;28:1600-4.
42. Amoli MM, Shelley E, Mattey DL, Garcia-Porrua C, Thomson W, Hajeer AH, et al. Intercellular adhesion molecule-1 gene polymorphisms in isolated polymyalgia rheumatica. J Rheumatol 2002;29:502-4.
43. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant-cell arteritis. Ann Intern Med 1994;121:484-91.
44. Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant-cell arteritis. Evidence for two components of the disease. J Clin Invest 1994;94:1134-40.
45. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990;29:456-8.
46. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041-8.
47. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-94.
48. Nemetz A, Nosti-Escanilla MP, Molnar T, Kope A, Kovacs A, Feher J, et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1999;49:527-31.
49. McGarry F, Walker R, Sturrock R, Field M. The -308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27. J Rheumatol 1999;26:1110-6.
50. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes Genomics 1994;19:382-4.
51. Boiardi L, Salvarani C, Timms JM, Silvestri T, Macchioni PL, Pulsatelli L, et al. Interleukin-1 cluster and tumor necrosis factor-α gene polymorphisms in polymyalgia rheumatica. Clin Exp Rheumatol 2000;18:675-81.
52. McDowell TL, Symons JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995;38:221-8.
53. Gonzalez-Gay MA, Di Giovine FS, Silvestri T, Amoli MM, Garcia-Porrua C, Thomson W, et al. Lack of association between IL-1 cluster and TNF-alpha gene polymorphisms and giant cell arteritis. Clin Exp Rheumatol 2002;20:431.
54. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991;88:1445-51.
55. Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics 1992;13:654-7.
56. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-4.
57. Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-42.
58. Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994;37:1380-5.
59. Blakemore AI, Cox A, Gonzalez AM, Maskil JK, Hughes ME, Wilson RM, et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996;97:369-74.
60. Amoli MM, Thomson W, Hajeer AH, Calvino MC, Garcia-Porrua C, Ollier WE, et al. Interleukin 1 receptor antagonist gene polymorphism is associated with severe renal involvement and renal sequelae in Henoch-Schönlein purpura. J Rheumatol 2002;29:1404-7.
61. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-60.
62. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997;94:3195-9.
63. Wilson AG, Duff GW. Relevance of tumour necrosis factor alpha gene polymorphism in rheumatic disease. Rheumatology (Oxford) 1999;38:681-3.
64. Olomolaiye O, Wood NAP, Bidwell JL. A novel NIaIII polymorphism in the human IL-6 promoter. Eur J Immunogenet 1998;25:267.
65. Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Mattey DL, Amoli MM, et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002;20:179-84.
66. Meliconi R, Pulsatelli L, Uguccioni M, Salvarani C, Macchioni P, Melchiorri C, et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 1996;39:1199-207.
67. Pulsatelli L, Meliconi R, Boiardi L, Macchioni P, Salvarani C, Facchini A. Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica. Clin Exp Rheumatol 1998;16:263-8.
68. Hajeer AH, al Sharif F, Ollier WE. A polymorphism at position -403 in the human RANTES promoter. Eur J Immunogenet 1999;26:375-6.
69. Makki RF, al Sharif F, Gonzalez-Gay MA, Garcia-Porrua C, Ollier WE, Hajeer AH. RANTES gene polymorphism in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Clin Exp Rheumatol 2000;18:391-3.
70. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
71. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5.
72. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
73. Gomez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, Vicario JL, et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999;42:989-92.
74. Garred P, Madsen HO, Petersen J, Marquart H, Hansen TM, Freiesleben Sorensen S, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998;25:1462-5.
75. Cooke SP, Forrest G, Venables PJ, Hajeer A. The delta32 deletion of CCR5 receptor in rheumatoid arthritis. Arthritis Rheum 1998;41:1135-6.
76. Salvarani C, Boiardi L, Timms JM, Silvestri T, Ranzi A, Macchioni PL, et al. Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. Clin Exp Rheumatol 2000;18:591-5.
77. Sundy JS, Haynes BF. Cytokines and adhesion molecules in the pathogenesis of vasculitis. Curr Rheumatol Rep 2000;2:402-10.
78. Collins T, Williams A, Johnston GI, Kim J, Eddy R, Shows T, et al. Structure and chromosomal location of the gene for endothelial-leukocyte adhesion molecule 1. J Biol Chem 1991;266:2466-73.
79. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859-73.
80. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci U S A 1987;84:9238-42.
81. Wenzel K, Felix S, Kleber FX, Brachold R, Menke T, Schattke S, Schulte KL, et al. E-selectin polymorphism and atherosclerosis: an association study. Hum Mol Genet 1994;3:1935-7.
82. Ye SQ, Usher D, Virgil D, Zhang LQ, Yochim SE, Gupta RA. PstI polymorphism detects the mutation of serine128 to arginine in CD 62E gene - a risk factor for coronary artery disease. J Biomed Sci 1999;6:18-21.
83. El-Magadmi M, Alansari A, Teh LS, Ordi J, Gul A, Inanc M, et al. Association of the A561C E-selectin polymorphism with systemic lupus erythematosus in 2 independent populations. J Rheumatol 2001;28:2650-2.
84. Amoli MM, Alansari A, El-Magadmi M, Thomson W, Hajeer AH, Calvino MC, et al. Lack of association between A561C E-selectin polymorphism and large and small-sized blood vessel vasculitides. Clin Exp Rheumatol 2002;20:575-6.
85. Machado EB, Michet CJ, Ballard DJ, Hunder GG, Beard CM, Chu CP, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum 1988;31:745-9.
86. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Scholmerich J, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998;83:2012-7.
87. Straub RH, Gluck T, Cutolo M, Georgi J, Helmke K, Scholmeric HJ, et al. The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford) 2000;39:624-31.
88. Cutolo M, Straub RH. Polymyalgia rheamatica: evidence for a hypothalamic-pituitary-adrenal axis-driven disease. Clin Exp Rheumatol 2000;18:655-8.
89. Piredda S, Prete C, Seriolo B, Marugo A, Foppiani L, Cutolo M, Assessment of HPA axis in rheumatic polymyalgia by desmopres and low-dose ACTH tests. J Endocrinol Invest 2000;23(suppl):S6-33.
90. Cutolo M, Sulli A, Pizzorni C, Craviotto C, Prete C, Foppiani L, et al. Cortisol, dehydroepiandrosterone sulfate, and androstenedione levels in patients with polymyalgia rheumatica during twelve months of glucocorticoid therapy. Ann N Y Acad Sci 2002;966:91-6.
91. Arbiser JL, Morton CC, Bruns GA, Majzoub JA Human corticotropin releasing hormone gene is located on the long arm of chromosome 8. Cytogenet Cell Genet 1988;47:113-6.
92. Baerwald CG, Panayi GS, Lanchbury JS. Corticotropin releasing hormone promoter region polymorphisms in rheumatoid arthritis. J Rheumatol 1997;24:215-6
93. Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Amoli MM, Thomson W, et al. Corticotropin releasing hormone promoter polymorphisms in giant cell arteritis and polymyalgia rheumatica. Clin Exp Rheumatol 2002;20:133-8.
94. Salvarani C, Boiardi L, Casali B, Olivieri I, Ciancio G, Cantini F, et al. Endothelial nitric oxide synthase gene polymorphisms in Behcet's disease. J Rheumatol 2002;29:535-40
95. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14.
96. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18.